Jenny Stanford Series on Nanomedicine Immune Aspects of Biopharmaceuticals and Nanomedicines

1. Current Immune Aspects of Biologics and Nanodrugs: An Overview
2. Immunological Issues with Medicines of Nano Size: The Price of Dimension Paradox
3. Immunotherapy and Vaccines
4. Site-Specific Antibody Conjugation for ADC and Beyond
5. Current Understanding of Interactions between Nanoparticles and the Immune System
6. Auto-antibodies as Biomarkers for Disease Diagnosis
7. The Acceleated Blood Clearance Phenomenon of PEGylated Nanocarriers
8. Anti-PEG Immunity Against PEGylated Therapeutics
9. Complement Activation: Challenges to Nanomedicine Development
10. Intravenous Immunoglobulin at the Borderline of Nanomedicines and Biologicals: Antithrombogenic Effect via Complement Attenuation
11. Lessons Learned from the Porcine CARPA Model: Constant and Variable Responses to Different Nanomedicines and Administration Protocols
12. Blood Cell Changes in Complement Activation-Related Pseudoallergy: Intertwining of Cellular and Humoral Interactions
13. Rodent Models of Complement Activation-Related Pseudoallergy: Inducers, Symptoms, Inhibitors and Reaction Mechanisms
14. Immune Reactions in the Delivery of RNA Interference-Based Therapeutics: Mechanisms and Opportunities
15. Lipid Nanoparticle Induced lmmunomodulatory Effects of siRNA
16. Nanovaccines against Intracellular Pathogens Using Coxiella burnetii as a Model Organism
17. lmmunogenicity Assessment for Therapeutic Protein Products
18. Assay Development and Validation for lmmunogenicity Testing of Therapeutic Protein Products
19. The "Sentinel": A Conceptual Nanomedical Strategy for the Enhancement of the Human Immune System
20. Immunotherapy for Gliomas and Other Intracranial Malignancies
21. Engineering Nanoparticles to Overcome Barriers to Immunotherapy
22. Metal-Based Nanoparticles and thelmmune System: Activation, Inflammation, and Potential Applications
23. Silica Nanoparticles Effects on Hemostasis
24. Valproate-lnduced Rodent Model of Autism Spectrum Disorder: Immunogenic Effects and Role of Microglia
25. Accelerated Blood Clearance Phenomenon and Complement Activation-Related Pseudoallergy: Two Sides of the Same Coin
26. Current and Rising Concepts in Immunotherapy: Biopharmaceuticals versus Nanomedicines
27. Characterization of the Interaction between Nanomedicines and Biological Components: In vitro Evaluation
28. Unwanted lmmunogenicity: From Risk Assessment to Risk Management
29. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials
30. SGT-53: A Novel Nanomedicine Capable of Augmenting Cancer Immunotherapy

The enormous advances in the immunologic aspects of biotherapeutics and nanomedicines in the past two decades has necessitated an authoritative and comprehensive reference source that can be relied upon by immunologists, biomedical researchers, clinicians, pharmaceutical companies, regulators, venture capitalists, and policy makers alike. This text provides a thorough understanding of immunology, therapeutic potential, clinical applications, adverse reactions, and approaches to overcoming immunotoxicity of biotherapeutics and nanomedicines. It also tackles critical, yet often overlooked topics such as immune aspects of nano-bio interactions, current FDA regulatory guidances, complement activation-related pseudoallergy (CARPA), advances in nanovaccines, and immunogenicity testing of protein therapeutics.